目的 探討糖尿樂膠囊聯(lián)合鹽酸吡格列酮片治療2型糖尿病的臨床療效。方法 選取2020年4月—2023年3月華北醫(yī)療健康集團(tuán)峰峰總醫(yī)院收治的100例2型糖尿病患者，將100例患者隨機(jī)分為對(duì)照組（50例）和治療組（50例）。對(duì)照組患者口服鹽酸吡格列酮片，2片/次，1次/d。治療組患者在對(duì)照組患者的基礎(chǔ)上口服糖尿樂膠囊，4粒/次，3次/d。兩組患者持續(xù)治療3個(gè)月。比較兩組臨床效果、臨床癥狀消失時(shí)間、血糖指標(biāo)和血清指標(biāo)。結(jié)果 治療后，治療組的總有效率為94.00%，對(duì)照組的總有效率為78.00%，組間差異顯著（P＜0.05）。治療后，治療組多飲、多尿、乏力消失時(shí)間均明顯短于對(duì)照組（P＜0.05）。治療后，兩組的空腹血糖（FPG）、餐后血糖（PPG）、糖化血紅蛋白（HbA1c）均低于治療前（P＜0.05），且治療組血糖指標(biāo)較對(duì)照組更低（P＜0.05）。治療后，兩組的血清中性粒細(xì)胞與淋巴細(xì)胞比率（NLR）、血清腎損傷分子-1（KIM-1）、中性粒細(xì)胞明膠酶相關(guān)載脂蛋白（NGAL）水平低于治療前（P＜0.05）；治療組的血清NLR、KIM-1、NGAL水平低于對(duì)照組（P＜0.05）。結(jié)論 糖尿樂膠囊聯(lián)合鹽酸吡格列酮片可提高2型糖尿病的療效，促進(jìn)癥狀好轉(zhuǎn)，進(jìn)一步降低血糖，有助于降低腎損傷。

Objective To investigate the clinical efficacy of Tangniaole Capsules combined with Pioglitazone Hydrochloride Tablets in treatment of type 2 diabetes mellitus. Methods Patients (100 cases) with type 2 diabetes mellitus in Fengfeng General Hospital of North China Medical and Health Group from April 2020 to March 2023 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Pioglitazone Hydrochloride Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Tangniaole Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 months. The clinical efficacies, main symptom resolution time, blood glucose indexes, and serum indexes in two groups were compared. Results After treatment, the total effective rate was 94.00% in the treatment group and 78.00% in the control group, with significant difference between groups (P < 0.05). After treatment, the disappearance time of polydipsia, polyuria, and fatigue in the treatment group was significantly shorter than those in the control group (P < 0.05). After treatment, FPG, PPG, and HbA1c in two groups were lower than those before treatment (P < 0.05), and the blood glucose index in the treatment group was lower than those in the control group (P < 0.05). After treatment, the serum levels of NLR, KIM-1, and NGAL in two groups were lower than those before treatment P < 0.05), and the levels of NLR, KIM-1 and NGAL in the treatment group were lower than those in the control group (P < 0.05). Conclusion Tangniaole Capsules combined with Pioglitazone Hydrochloride Tablets can improve the curative effect of type 2 diabetes mellitus, further reduce blood sugar, promote the improvement of symptoms, and help reduce kidney damage.

R977

邯鄲市科技技術(shù)研究與發(fā)展計(jì)劃項(xiàng)目（19422083012-7）